Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$160.65 USD
+0.96 (0.60%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $160.64 -0.01 (-0.01%) 7:12 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$160.65 USD
+0.96 (0.60%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $160.64 -0.01 (-0.01%) 7:12 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
Zacks News
FATE To End Janssen Deal and Prioritize Pipeline Development
by Zacks Equity Research
FATE decides not to continue its collaboration and option agreement with Janssen. The company also conducts a strategic review.
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should Vanguard High Dividend Yield ETF (VYM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VYM
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $178.19, marking a +0.87% move from the previous day.
The Zacks Analyst Blog Highlights Apple, Johnson & Johnson, CSX, American International Group and CenterPoint Energy
by Zacks Equity Research
Apple, Johnson & Johnson, CSX, American International Group and CenterPoint Energy are included in this Analyst Blog.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Earnings Outlook for 2023 and Featured Reports for Apple, JNJ, & Others
by Sheraz Mian
Today's Research Daily an earnings update and features new research reports on Apple (AAPL), JNJ (JNJ), CSX (CSX) & Others.
Johnson & Johnson (JNJ) Stock Moves -0.43%: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $176.66 in the latest trading session, marking a -0.43% move from the prior day.
Should SPDR Portfolio S&P 500 Value ETF (SPYV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPYV
Gilead (GILD) Gets FDA Nod for Twice-Yearly HIV Treatment
by Zacks Equity Research
Gilead'ls (GILD) HIV franchise gets a boost with FDA's approval of twice-yearly HIV treatment Sunlenca for the treatment of HIV-1 infection in heavily treatment-experienced adults with multi-drug resistance.
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AstraZeneca (AZN) Gets EU Nod to Expanded Use of 2 Cancer Drugs
by Zacks Equity Research
The European Commission approves AstraZeneca's (AZN) two key cancer drugs Lynparza and Imfinzi for expanded use.
Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PFM
Is ALPS O'Shares U.S. Quality Dividend ETF (OUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for OUSA
Johnson & Johnson (JNJ) Stock Moves -0.11%: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $175.48, marking a -0.11% move from the previous day.
FDA Delays Decision on AstraZeneca (AZN), Merck's Lynparza sNDA
by Zacks Equity Research
The FDA extends the review period of AstraZeneca (AZN)/Merck's filing seeking label expansion for Lynparza's indication in prostate cancer. The FDA intends to use this time to review the submission.
Zacks Industry Outlook Highlights Johnson & Johnson, Novo Nordisk, Merck and AstraZeneca
by Zacks Equity Research
Johnson & Johnson, Novo Nordisk, Merck and AstraZeneca have been highlighted in this Industry Outlook article.
4 Large Drug Stocks to Watch in a Booming Industry
by Kinjel Shah
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Johnson & Johnson (JNJ), Novo Nordisk (NVO), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $177.84, moving +1.19% from the previous trading session.
The Return of "Merger Monday"
by Andrew Rocco
Two major deals in the biotech and software industry were inked this weekend.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
ETF Investing Strategies for 2023
by Neena Mishra
We discuss the market outlook and investing strategies for 2023.
Is Vanguard Dividend Appreciation ETF (VIG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VIG
Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $176.10, moving -1.5% from the previous trading session.